EPCAM and prostate carcinoma: It has been reported that EpCAM is involved in the response to chemotherapy/radiotherapy in a xenograft model of prostate cancer and that its knockdown causes significant tumor growth inhibition and induction of sensitivity to chemotherapy/radiotherapy 43.